UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 4, 2008
-----------------
BioForce Nanosciences Holdings, Inc.
(Exact name of registrant as specified in its charter)
Nevada 000-51074 74-3078125
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
1615 Golden Aspen Drive, Suite 101
Ames, Iowa 50010
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (515) 233-8333
-----------------
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
- --------------------------------------------------------------------------------
Section 7 - Regulation FD
Item 7.01 Regulation FD Disclosure.
Beginning in February 2008, our management will make presentations to investors
using the slide presentation attached to this report on Form 8-K as Exhibit
99.1.
The slide presentation contained in the exhibit includes statements intended as
"forward-looking statements," which are subject to the cautionary statement
about forward-looking statements set forth in the exhibit. The information
contained in this Item 7.01 and the attached Exhibit 99.1 is furnished to, but
not filed with, the Securities and Exchange Commission. The information
contained herein and in the accompanying exhibit shall not be incorporated by
reference to any of our filings, whether made before or after the date hereof,
regardless of any general incorporation language in such filing, unless
expressly incorporated by specific reference to such filing. The filing of this
current report on Form 8-K is not an admission or determination as to the
materiality or completeness of any information in this Item 7.01 or the attached
Exhibit 99.1.
- --------------------------------------------------------------------------------
Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
- ----------- -----------
99.1 Presentation dated February 2008
- --------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
BioForce Nanosciences Holdings, Inc.
Date: February 4, 2008 By: /s/ Gregory D. Brown
--------------------------------
Gregory D. Brown
Chief Financial Officer
- --------------------------------------------------------------------------------
INDEX TO EXHIBITS
Exhibit No. Description
- ----------- -----------
99.1 Presentation dated February 2008